Physician profile
Roman Schwartsman
NPI 1356378723
$358,452.76
in general payments reported to CMS, 2019-2025
9 companies · $11K in 2025
The $11K reported for 2025 was more than what 88% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $321K · 2023: $26K · 2024: $647 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $37K · Travel and Lodging: $596 · Food and Beverage: $92.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $37,111.40 |
| Travel and Lodging | $596.20 |
| Food and Beverage | $92.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $357,650.52 | 2022-2025 | Engage Partial Knee System |
| Microport Orthopedics INC | $647.21 | 2024 | Mpo Hip System |
| Engage Uni, LLC | $114.00 | 2021 | |
| Medacta USA, INC. | $22.91 | 2025 | Gmk Revision |
| Steelhead Surgical INC | $18.12 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,973,472.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Schwartsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.